In short
Clinical trials of Interferon Beta-1A are studying how it performs in different patient groups, especially people with multiple sclerosis. These studies look at outcomes such as disease activity, relapse rates, disability progression, and safety. Some trials also compare Interferon Beta-1A with other treatments or with treatment withdrawal.
Key points
- Clinical trials involving Interferon Beta-1A are mostly focused on multiple sclerosis, including relapsing-remitting, secondary progressive, and progressive forms. The studies range from Phase 2 to Phase 3 and include adults, older adults, and in one study, pediatric participants. Trial goals include measuring relapse rates, MRI activity, disability progression, walking speed, and long-term safety. Some studies compare Interferon Beta-1A with other disease-modifying treatments, while others test treatment withdrawal or de-escalation strategies. One non-MS trial includes Interferon Beta-1A as part of a study in EBV-positive nasopharyngeal carcinoma. Another trial uses a placebo matched to Interferon Beta-1A in a respiratory virus study.
Clinical trials overview
The trial data show that Interferon Beta-1A is being studied mainly in multiple sclerosis (MS), especially relapsing-remitting MS and other progressive forms of MS. These studies look at whether treatment can reduce disease activity, slow disability, and improve patient outcomes over time.
Multiple sclerosis studies
Several trials include relapsing-remitting multiple sclerosis (RRMS), which is a form of MS where symptoms worsen in attacks and then improve or settle down. One Phase 3 study in newly diagnosed RRMS patients compares ofatumumab with first-line disease-modifying treatments chosen by the physician, and Interferon Beta-1A is one of the treatments listed in the study options. The main outcome in that study is NEDA-3, which means no clinical relapses, no new MRI activity, and no confirmed worsening of disability.
Another Phase 3 study in older people with stable RRMS looks at whether treatment can be stopped without causing more disease activity. This study includes several MS disease-modifying therapies, including Interferon Beta-1A, and follows patients for 2 years. The trial measures the time to first clinical or radiological disease activity, which means the first sign of a relapse or a change seen on MRI.
A separate Phase 3 study focuses on people with inactive secondary progressive MS who are older than 50 years. In this trial, Interferon Beta-1A is among the therapies being withdrawn or continued, and the study compares treatment continuation with treatment withdrawal. The main endpoint is disability progression confirmed at 6 months, which means a lasting worsening in function measured on the EDSS scale.
There is also a Phase 3 pediatric RRMS study of BIIB017, described as peginterferon beta-1a, which evaluates safety, tolerability, efficacy, and pharmacokinetics in children and adolescents with RRMS. The study measures annualized relapse rate at Week 48 and later tracks adverse events and long-term outcomes.
One Phase 2 study in progressive MS is designed to test whether add-on treatment can delay disease progression compared with placebo. Although the main study drug is metformin, the treatment list includes Betaferon, AVONEX, Plegridy, Rebif, and other MS therapies, showing that Interferon Beta-1A-related products are part of the treatment background in this progressive MS research setting. The key outcome is change in walking speed measured by the T25FW test over 96 weeks.
Other conditions studied
Not all trials are in MS. One Phase 2 study in EBV-positive nasopharyngeal carcinoma includes Interferon Beta-1A in the treatment list together with nivolumab, cisplatin, 5-fluorouracil, and other drugs. The study includes children, adolescents, and young adults up to 25 years with locoregional disease, and it measures complete remission rate on MRI and PET/CT after induction treatment.
Another Phase 2 respiratory virus study uses a placebo matched to Interferon Beta-1A for inhalation. This trial is in mechanically ventilated patients with confirmed respiratory virus infection and measures safety first, then all-cause mortality within 28 days.
Trial phases and designs
The listed studies are mainly Phase 3 and Phase 2 trials. Phase 3 studies usually compare treatments in larger groups, while Phase 2 studies often focus on early signals of benefit, safety, and how the treatment performs in a smaller group.
Several studies use a randomized design, which means people are assigned by chance to different treatment groups. Some are open-label, meaning both the research team and the patient know which treatment is being given, while others are placebo-controlled or triple-blind, meaning the treatment assignment is hidden to reduce bias.
Key endpoints measured in the trials
The main study outcomes focus on how MS changes over time. These include walking speed measured by the T25FW test, which checks how fast a person can walk 25 feet. They also include relapse rate, MRI changes, disability worsening, and whether a patient has no disease activity at all.
In the RRMS studies, the endpoints include annualized relapse rate and NEDA-3 status, which combines relapse, MRI, and disability measures into one result. In the older MS withdrawal studies, the endpoint is time to first disease activity or confirmed disability progression. In the cancer study, the endpoint is complete remission rate, which means the share of patients who have a complete response on imaging tests.
Safety is also important in several trials. The pediatric RRMS study tracks adverse events, serious adverse events, and treatment discontinuation because of side effects. The respiratory virus study also measures adverse events and serious adverse events, including breathing and heart-related worsening.
Who the trials include
The target populations are quite different across studies. Some trials include newly diagnosed, treatment-naïve adults with RRMS, meaning they have not yet received MS disease-modifying treatment. Others focus on older adults with stable or inactive MS, where the goal is to see whether treatment can be safely continued or stopped.
The pediatric study includes children with RRMS, which is important because younger patients may respond differently and need long-term follow-up. The cancer study includes children, adolescents, and young adults up to age 25 with EBV-positive nasopharyngeal carcinoma. The respiratory virus trial includes mechanically ventilated patients with confirmed infection, which is a very different and much more acute patient group.
What these trials mean for patients
Overall, the trial data show that Interferon Beta-1A is being studied mostly as part of MS treatment research, especially in people with relapsing forms of the disease. The studies are trying to understand whether treatment helps prevent relapses, reduce MRI activity, slow disability, or support safe treatment changes over time.
Some trials do not test Interferon Beta-1A as the main study drug, but they still include it as a comparator, background therapy, or placebo match. This means the research is not only about whether the treatment works, but also about where it fits in modern treatment strategies for different patient groups.